-
Je něco špatně v tomto záznamu ?
Post-acute phase and sequelae management of epidermal necrolysis: an international, multidisciplinary DELPHI-based consensus
S. Ingen-Housz-Oro, V. Schmidt, MM. Ameri, R. Abe, A. Brassard, A. Mostaghimi, AS. Paller, A. Romano, B. Didona, BH. Kaffenberger, B. Ben Said, BYH. Thong, B. Ramsay, E. Brezinova, B. Milpied, CG. Mortz, CY. Chu, C. Sotozono, J. Gueudry, DG....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
BioMedCentral
od 2006-12-01
BioMedCentral Open Access
od 2006
Directory of Open Access Journals
od 2006
Free Medical Journals
od 2006
PubMed Central
od 2006
Europe PubMed Central
od 2006
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2006-01-01
Open Access Digital Library
od 2006-01-01
Medline Complete (EBSCOhost)
od 2006-01-01
Health & Medicine (ProQuest)
od 2009-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2006
Springer Nature OA/Free Journals
od 2006-12-01
- MeSH
- konsensus MeSH
- kůže MeSH
- lidé MeSH
- progrese nemoci MeSH
- Stevensův-Johnsonův syndrom * komplikace MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND: Long-term sequelae are frequent and often disabling after epidermal necrolysis (Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)). However, consensus on the modalities of management of these sequelae is lacking. OBJECTIVES: We conducted an international multicentric DELPHI exercise to establish a multidisciplinary expert consensus to standardize recommendations regarding management of SJS/TEN sequelae. METHODS: Participants were sent a survey via the online tool "Survey Monkey" consisting of 54 statements organized into 8 topics: general recommendations, professionals involved, skin, oral mucosa and teeth, eyes, genital area, mental health, and allergy workup. Participants evaluated the level of appropriateness of each statement on a scale of 1 (extremely inappropriate) to 9 (extremely appropriate). Results were analyzed according to the RAND/UCLA Appropriateness Method. RESULTS: Fifty-two healthcare professionals participated. After the first round, a consensus was obtained for 100% of 54 initially proposed statements (disagreement index < 1). Among them, 50 statements were agreed upon as 'appropriate'; four statements were considered 'uncertain', and ultimately finally discarded. CONCLUSIONS: Our DELPHI-based expert consensus should help guide physicians in conducting a prolonged multidisciplinary follow-up of sequelae in SJS-TEN.
Allergy Unit IBIMA Regional University Hospital of Malaga UMA Málaga Spain
Burn Service Boston Shriners Hospital for Children Boston MA USA
Christine Kühne Center for Allergy Research and Education Davos Switzerland
Cornea and External Eye Disease Service Moorfields Eye Hospital London UK
Department of Adult and Pediatric Dermatology Bordeaux University Hospitals Bordeaux France
Department of Dermatology and Cutaneous Surgery University of South Florida Tampa FL USA
Department of Dermatology AP HP Henri Mondor Hospital 1 Rue Gustave Eiffel 94000 Créteil France
Department of Dermatology Brigham and Women's Hospital Boston MA USA
Department of Dermatology Brigham and Women's Hospital Harvard Medical School Boston MA USA
Department of Dermatology CHU Edouard Herriot Lyon France
Department of Dermatology King's College Hospital NHS Foundation Trust London UK
Department of Dermatology Northwestern University Feinberg School of Medicine Chicago IL USA
Department of Dermatology UC Davis Medical Center Sacramento CA USA
Department of Dermatology University Hospital Limerick Limerick Ireland
Department of Dermatology University Hospital Munich University of Ludwig Maximilian Munich Germany
Department of Dermatology University Hospital Zurich Zurich Switzerland
Department of Dermatology University Hospitals Birmingham NHS Foundation Trust Birmingham UK
Department of Dermatology University of California Davis Sacramento CA USA
Department of Dermatology University of Toronto Toronto ON Canada
Department of Internal Medicine Centre Hospitalier Intercommunal de Créteil Créteil France
Department of Medicine University of Toronto Toronto Canada
Department of Medicine Vanderbilt University Medical Center Nashville TN USA
Department of Nursing and Midwifery University of Limerick Limerick Ireland
Department of Ophthalmology CHU Bichat Claude Bernard Paris France
Department of Ophthalmology CHU Charles Nicolle Rouen France
Department of Oral Medicine Guy's and St Thomas' NHS Foundation Trust London UK
Department of Psychology University of Limerick Limerick Ireland
Department of Rheumatology Allergy and Immunology Tan Tock Seng Hospital Singapore Singapore
Department of Surgery Harvard Medical School Boston MA USA
Division of Burns Massachusetts General Hospital Boston 02114 USA
Division of Burns Massachusetts General Hospital Boston MA USA
EpiDermE Université Paris Est Créteil Créteil France
Faculty of Medicine University of Zurich Zurich Switzerland
Fondation Ophtalmologique Adolphe de Rothschild Paris France
Institute for Immunology and Infectious Diseases Murdoch University Murdoch WA Australia
Medical School University of Western Australia Perth WA 6009 Australia
Moorfields Eye Hospital NHS Foundation Trust The UCL Institute of Ophthalmology London UK
Oasi Research Institute IRCCS Troina Italy
Ophthalmology Bon Secours Hospital Cork Ireland
Rare Disease Unit 1 Dermatology Division Istituto Dermopatico Dell'Immacolata IRCCS Rome Italy
Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL Créteil France
St John's Institute of Dermatology Guy's and St Thomas' Hospital London UK
Sunnybrook Health Sciences Centre Toronto ON Canada
The Ohio State University Wexner Medical Center Division of Dermatology Upper Arlington OH USA
ToxiTEN Group European Reference Network for Rare Skin Diseases Paris France
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23004122
- 003
- CZ-PrNML
- 005
- 20230425141116.0
- 007
- ta
- 008
- 230418s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1186/s13023-023-02631-7 $2 doi
- 035 __
- $a (PubMed)36814255
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Ingen-Housz-Oro, S $u Department of Dermatology, AP-HP, Henri Mondor Hospital, 1 Rue Gustave Eiffel, 94000, Créteil, France. saskia.oro@aphp.fr $u ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France. saskia.oro@aphp.fr $u Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France. saskia.oro@aphp.fr $u EpiDermE, Université Paris Est Créteil, Créteil, France. saskia.oro@aphp.fr $1 https://orcid.org/0000000253837096
- 245 10
- $a Post-acute phase and sequelae management of epidermal necrolysis: an international, multidisciplinary DELPHI-based consensus / $c S. Ingen-Housz-Oro, V. Schmidt, MM. Ameri, R. Abe, A. Brassard, A. Mostaghimi, AS. Paller, A. Romano, B. Didona, BH. Kaffenberger, B. Ben Said, BYH. Thong, B. Ramsay, E. Brezinova, B. Milpied, CG. Mortz, CY. Chu, C. Sotozono, J. Gueudry, DG. Fortune, SM. Dridi, D. Tartar, G. Do-Pham, E. Gabison, EJ. Phillips, F. Lewis, C. Salavastru, B. Horvath, J. Dart, J. Setterfield, J. Newman, JT. Schulz, A. Delcampe, K. Brockow, L. Seminario-Vidal, L. Jörg, MP. Watson, M. Gonçalo, M. Lucas, M. Torres, MH. Noe, N. Hama, NH. Shear, P. O'Reilly, P. Wolkenstein, P. Romanelli, RP. Dodiuk-Gad, RG. Micheletti, GS. Tiplica, R. Sheridan, S. Rauz, S. Ahmad, SL. Chua, TH. Flynn, W. Pichler, ST. Le, E. Maverakis, S. Walsh, LE. French, MC. Brüggen
- 520 9_
- $a BACKGROUND: Long-term sequelae are frequent and often disabling after epidermal necrolysis (Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN)). However, consensus on the modalities of management of these sequelae is lacking. OBJECTIVES: We conducted an international multicentric DELPHI exercise to establish a multidisciplinary expert consensus to standardize recommendations regarding management of SJS/TEN sequelae. METHODS: Participants were sent a survey via the online tool "Survey Monkey" consisting of 54 statements organized into 8 topics: general recommendations, professionals involved, skin, oral mucosa and teeth, eyes, genital area, mental health, and allergy workup. Participants evaluated the level of appropriateness of each statement on a scale of 1 (extremely inappropriate) to 9 (extremely appropriate). Results were analyzed according to the RAND/UCLA Appropriateness Method. RESULTS: Fifty-two healthcare professionals participated. After the first round, a consensus was obtained for 100% of 54 initially proposed statements (disagreement index < 1). Among them, 50 statements were agreed upon as 'appropriate'; four statements were considered 'uncertain', and ultimately finally discarded. CONCLUSIONS: Our DELPHI-based expert consensus should help guide physicians in conducting a prolonged multidisciplinary follow-up of sequelae in SJS-TEN.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a Stevensův-Johnsonův syndrom $x komplikace $7 D013262
- 650 _2
- $a konsensus $7 D032921
- 650 _2
- $a kůže $7 D012867
- 650 _2
- $a progrese nemoci $7 D018450
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Schmidt, V $u University Hospital Basel, Basel, Switzerland $u Faculty of Medicine, University of Zurich, Zurich, Switzerland
- 700 1_
- $a Ameri, M M $u Faculty of Medicine, University of Zurich, Zurich, Switzerland. saskia.oro@aphp.fr $u Department of Dermatology, University Hospital Zurich, Zurich, Switzerland. saskia.oro@aphp.fr $u Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland. saskia.oro@aphp.fr
- 700 1_
- $a Abe, R $u Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
- 700 1_
- $a Brassard, A $u Department of Dermatology, UC Davis Medical Center, Sacramento, CA, USA
- 700 1_
- $a Mostaghimi, A $u Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA
- 700 1_
- $a Paller, A S $u Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
- 700 1_
- $a Romano, A $u Oasi Research Institute-IRCCS, Troina, Italy
- 700 1_
- $a Didona, B $u ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France $u Rare Disease Unit, I Dermatology Division, Istituto Dermopatico Dell'Immacolata, IRCCS, Rome, Italy
- 700 1_
- $a Kaffenberger, B H $u ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France $u The Ohio State University Wexner Medical Center Division of Dermatology, Upper Arlington, OH, USA
- 700 1_
- $a Ben Said, B $u ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France $u Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France $u Department of Dermatology, CHU Edouard Herriot, Lyon, France
- 700 1_
- $a Thong, B Y H $u Department of Rheumatology, Allergy and Immunology, Tan Tock Seng Hospital, Singapore, Singapore
- 700 1_
- $a Ramsay, B $u Department of Dermatology, University Hospital Limerick, Limerick, Ireland
- 700 1_
- $a Brezinova, E $u ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France $u First Department of Dermatovenereology, Masaryk University Faculty of Medicine, St. Ann's Faculty Hospital in Brno, Brno, Czech Republic
- 700 1_
- $a Milpied, B $u ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France $u Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France $u Department of Adult and Pediatric Dermatology, Bordeaux University Hospitals, Bordeaux, France
- 700 1_
- $a Mortz, C G $u Department of Dermatology and Allergy Center, Odense Research Center for Anaphylaxis (ORCA), Odense University Hospital, Odense, Denmark
- 700 1_
- $a Chu, C Y $u Department of Dermatology, National Taiwan University Hospital, National Taiwan University College of Medicine, No. 7, Chung-Shan South Road, Taipei, 10002, Taiwan
- 700 1_
- $a Sotozono, C $u Department of Ophthalmology, Kyoto Prefectural University of Medicine, 465 Kajii-Cho, Hirokoji-Agaru, Kawaramach-Dori, Kamigyo-Ku, Kyoto, 602-0841, Japan
- 700 1_
- $a Gueudry, J $u Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France $u Department of Ophthalmology, CHU Charles-Nicolle, Rouen, France
- 700 1_
- $a Fortune, D G $u Department of Psychology, University of Limerick, Limerick, Ireland
- 700 1_
- $a Dridi, S M $u Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France $u MICORALIS Laboratory, Department of Periodontology, Faculty of Dentistry, Côte d'Azur University, Saint Roch Hospital, Nice, France
- 700 1_
- $a Tartar, D $u Department of Dermatology, University of California Davis, Sacramento, CA, USA
- 700 1_
- $a Do-Pham, G $u Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France $u Department of Internal Medicine, Centre Hospitalier Intercommunal de Créteil, Créteil, France
- 700 1_
- $a Gabison, E $u Fondation Ophtalmologique Adolphe de Rothschild, Paris, France
- 700 1_
- $a Phillips, E J $u Institute for Immunology and Infectious Diseases, Murdoch University, Murdoch, WA, Australia $u Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA
- 700 1_
- $a Lewis, F $u St John's Institute of Dermatology, Guy's and St Thomas' Hospital, London, UK
- 700 1_
- $a Salavastru, C $u ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France $u Department of Paediatric Dermatology, Colentina Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
- 700 1_
- $a Horvath, B $u ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France $u Department of Dermatology, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands
- 700 1_
- $a Dart, J $u Moorfields Eye Hospital NHS Foundation Trust, The UCL Institute of Ophthalmology, London, UK
- 700 1_
- $a Setterfield, J $u ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France $u Department of Oral Medicine, Guy's and St Thomas' NHS Foundation Trust, London, UK
- 700 1_
- $a Newman, J $u Department of Dermatology, King's College Hospital NHS Foundation Trust, London, UK
- 700 1_
- $a Schulz, J T $u Division of Burns, Massachusetts General Hospital, Boston, 02114, USA
- 700 1_
- $a Delcampe, A $u Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France $u Department of Ophthalmology, CHU Charles-Nicolle, Rouen, France $u Fondation Ophtalmologique Adolphe de Rothschild, Paris, France $u Department of Ophthalmology, CHU Bichat-Claude Bernard, Paris, France
- 700 1_
- $a Brockow, K $u Department of Dermatology and Allergy Biederstein, School of Medicine, Technical University of Munich, Munich, Germany
- 700 1_
- $a Seminario-Vidal, L $u Department of Dermatology and Cutaneous Surgery, University of South Florida, Tampa, FL, USA
- 700 1_
- $a Jörg, L $u Department of Dermatology, University Hospital Zurich, Zurich, Switzerland $u Division of Allergology and Clinical Immunology, Department of Pneumology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
- 700 1_
- $a Watson, M P $u Cornea and External Eye Disease Service, Moorfields Eye Hospital, London, UK
- 700 1_
- $a Gonçalo, M $u Department of Dermatology, Coimbra University Hospital Center, Faculty of Medicine, University of Coimbra, Coimbra, Portugal
- 700 1_
- $a Lucas, M $u Medical School, University of Western Australia, Perth, WA, 6009, Australia $u Department of Immunology, Sir Charles Gairdner Hospital, Pathwest Laboratory Medicine, Perth, WA, 6009, Australia
- 700 1_
- $a Torres, M $u Allergy Unit, IBIMA-Regional University Hospital of Malaga-UMA, Málaga, Spain
- 700 1_
- $a Noe, M H $u Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
- 700 1_
- $a Hama, N $u Division of Dermatology, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan
- 700 1_
- $a Shear, N H $u Department of Dermatology, University of Toronto, Toronto, ON, Canada $u Sunnybrook Health Sciences Centre, Toronto, ON, Canada
- 700 1_
- $a O'Reilly, P $u Department of Nursing and Midwifery, University of Limerick, Limerick, Ireland
- 700 1_
- $a Wolkenstein, P $u Department of Dermatology, AP-HP, Henri Mondor Hospital, 1 Rue Gustave Eiffel, 94000, Créteil, France $u ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France $u Reference Center for Toxic Bullous Dermatoses and Severe Drug Reactions TOXIBUL, Créteil, France
- 700 1_
- $a Romanelli, P $u Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, Miami, FL, USA
- 700 1_
- $a Dodiuk-Gad, R P $u Dermatology Department, Emek Medical Center, Bruce Rappaport Faculty of Medicine, Technion - Institute of Technology, Haifa, Israel $u Department of Medicine, University of Toronto, Toronto, Canada
- 700 1_
- $a Micheletti, R G $u Department of Dermatology and Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
- 700 1_
- $a Tiplica, G S $u ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France $u 2Nd Department of Dermatology, Colentina Clinical Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania
- 700 1_
- $a Sheridan, R $u Burn Service, Boston Shriners Hospital for Children, Boston, MA, USA $u Division of Burns, Massachusetts General Hospital, Boston, MA, USA $u Department of Surgery, Harvard Medical School, Boston, MA, USA
- 700 1_
- $a Rauz, S $u Academic Unit of Ophthalmology, Birmingham and Midland Eye Centre, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK
- 700 1_
- $a Ahmad, S $u Moorfields Eye Hospital NHS Foundation Trust, The UCL Institute of Ophthalmology, London, UK
- 700 1_
- $a Chua, S L $u ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France $u Department of Dermatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
- 700 1_
- $a Flynn, T H $u Ophthalmology, Bon Secours Hospital, Cork, Ireland
- 700 1_
- $a Pichler, W $u ADR-AC GmbH, Bern, Switzerland
- 700 1_
- $a Le, S T $u Department of Dermatology, UC Davis Medical Center, Sacramento, CA, USA
- 700 1_
- $a Maverakis, E $u Department of Dermatology, UC Davis Medical Center, Sacramento, CA, USA
- 700 1_
- $a Walsh, S $u ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France $u Department of Dermatology, King's College Hospital NHS Foundation Trust, London, UK
- 700 1_
- $a French, L E $u ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France $u Department of Dermatology, University Hospital, Munich University of Ludwig Maximilian, Munich, Germany $u Dr Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL, USA
- 700 1_
- $a Brüggen, M C $u ToxiTEN Group, European Reference Network for Rare Skin Diseases, Paris, France $u Faculty of Medicine, University of Zurich, Zurich, Switzerland $u Department of Dermatology, University Hospital Zurich, Zurich, Switzerland $u Christine Kühne-Center for Allergy Research and Education, Davos, Switzerland
- 773 0_
- $w MED00165365 $t Orphanet journal of rare diseases $x 1750-1172 $g Roč. 18, č. 1 (2023), s. 33
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/36814255 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425141113 $b ABA008
- 999 __
- $a ok $b bmc $g 1924657 $s 1190331
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 18 $c 1 $d 33 $e 20230222 $i 1750-1172 $m Orphanet journal of rare diseases $n Orphanet J Rare Dis $x MED00165365
- LZP __
- $a Pubmed-20230418
